

Katia Cannita

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6897500/publications.pdf>

Version: 2024-02-01

29
papers

324
citations

933447

10
h-index

888059

17
g-index

29
all docs

29
docs citations

29
times ranked

715
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinicians'™ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life" Case-Control Study. <i>Clinical Colorectal Cancer</i> , 2021, , .	2.3	8
2	Clinical and psychometric validation of the BreSAS questionnaire module for symptom assessment among breast cancer survivors. <i>Supportive Care in Cancer</i> , 2020, 28, 1051-1058.	2.2	0
3	Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study. <i>Cancers</i> , 2020, 12, 1259.	3.7	19
4	Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 1094-1101.	1.3	2
5	Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study. <i>Scientific Reports</i> , 2020, 10, 1456.	3.3	64
6	Weighing the role of concomitant medications during PD-1/PD-L1 checkpoint blockade: A preliminary analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15132-e15132.	1.6	1
7	Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2365-2373.	2.5	9
8	<p>Weekly alternate intensive regimen FlrB/FOx in metastatic colorectal cancer patients: an update from clinical practice</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2159-2170.	2.0	8
9	Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. <i>Journal of Cancer</i> , 2019, 10, 5926-5934.	2.5	24
10	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor"positive, advanced breast cancer: A real"world experience. <i>Journal of Cellular Physiology</i> , 2019, 234, 7708-7717.	4.1	21
11	Long-term toxicity profile of trastuzumab emtansine (T-DM1): A multicenter real-life study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e12507-e12507.	1.6	2
12	Multicentric retrospective analysis of platinum"pemetrexed regimens as first"line therapy in non"squamous non"small cell lung cancer patients: A "snapshot"from clinical practice. <i>Thoracic Cancer</i> , 2018, 9, 241-252.	1.9	6
13	Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the <i>FAMIL-L1</i> study. <i>Immunotherapy</i> , 2018, 10, 643-655.	2.0	15
14	Where are we with treatment options after first line in small cell lung cancer? "report of two opposite cases treated with CAPTEM regimen and possible perspectives. <i>Journal of Thoracic Disease</i> , 2018, 10, E520-E525.	1.4	0
15	Timed"flat infusion of 5"fluorouracil with docetaxel and oxaliplatin as first"line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen. <i>Oncology Reports</i> , 2018, 40, 803-812.	2.6	3
16	First-line chemotherapy with docetaxel, oxaliplatin, and timed-flat infusion 5Fluorouracil in metastatic gastro-esophageal adenocarcinomas: The experience with FD/FOx regimen.. <i>Journal of Clinical Oncology</i> , 2018, 36, 178-178.	1.6	0
17	Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of <i>PIK3CA</i> mutations. <i>Oncotarget</i> , 2018, 9, 27380-27396.	1.8	6
18	A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. <i>Oncotarget</i> , 2017, 8, 56921-56931.	1.8	53

#	ARTICLE	IF	CITATIONS
19	Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis. <i>Oncotarget</i> , 2017, 8, 72031-72043.	1.8	6
20	Topical menthol for treatment of chemotherapy-induced peripheral neuropathy. <i>Indian Journal of Palliative Care</i> , 2017, 23, 350.	1.0	10
21	Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer. <i>Bone</i> , 2016, 87, 169-175.	2.9	16
22	New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting. <i>Cancer Medicine</i> , 2016, 5, 2232-2239.	2.8	7
23	The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 190-202.	4.4	24
24	Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice. <i>BioMed Research International</i> , 2014, 2014, 1-11.	1.9	10
25	Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for Flr-B/FOx intensive regimen. <i>International Journal of Oncology</i> , 2014, 44, 1820-1830.	3.3	10
26	c.35 G > A KRAS-mutant genotype and clinical outcome of patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 512-512.	1.6	0
27	Prognostic relevance of KRAS genotype and the prevalent C.35 G > a mutation in metastatic colorectal cancer (MCRC) patients fitting for intensive Flr-B/FOx triplet chemotherapy plus bevacizumab.. <i>Journal of Clinical Oncology</i> , 2014, 32, e14575-e14575.	1.6	0
28	Worse prognosis of KRAS C.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with first-line triplet chemotherapy plus bevacizumab (Flr-B/FOx) and post-progression.. <i>Journal of Clinical Oncology</i> , 2013, 31, e14596-e14596.	1.6	0
29	Different clinical outcome of metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (Flr-B/FOx) according to <i>KRAS </i>genotype and disease extension.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14010-e14010.	1.6	0